Señales en vivo de EXAI | Maximiza tus Ganancias con Getagraph.com

COMPRAR 106817 min ago

@ $5.91

Emitido: 14 feb 2024 @ 15:27

Retorno: -31.81%

Señal anterior: feb 14 - 10:17

Señal anterior: Vender

Retorno: -2.24 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	384 502
Volumen promedio	732 390
Capitalización de mercado	506.58M
EPS	$0 ( 2024-03-28 )
Próxima fecha de ganancias	( $-0.370 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.74
ATR14	$0.00600 (0.15%)

Volumen Correlación

Largo: 0.34 (neutral)

Corto: 0.34 (neutral)

Signal:(54.919) Neutral

Exscientia plc Correlación

10 Correlaciones Más Positivas
TLGT	0.858
VINC	0.855
SVAC	0.848
EVOK	0.846
IMUX	0.82
FEYE	0.816
RMRM	0.816
ANGI	0.809
MKSI	0.805

10 Correlaciones Más Negativas
AMRB	-0.894
MMAC	-0.841
JCOM	-0.832
NETE	-0.82
GOODM	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Exscientia plc Correlación - Moneda/Commodity

-0.82
( strong negative )

0.49
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

-0.18
( neutral )

Exscientia plc Finanzas

Annual	2023
Ingresos:	$24.96M
Beneficio Bruto:	$-28.48M (-114.12 %)
EPS:	$-1.460

FY	2023
Ingresos:	$24.96M
Beneficio Bruto:	$-28.48M (-114.12 %)
EPS:	$-1.460

FY	2022
Ingresos:	$32.90M
Beneficio Bruto:	$-7.30M (-22.19 %)
EPS:	$-1.170

Financial Reports:

No articles found.

Exscientia plc

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.